Recent insider trends for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have caught the attention of investors. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock. In the case of COLL, the data has some interesting implications for where the stock might be headed.
Institutions own 80.14% of Collegium Pharmaceutical, Inc. (COLL)’s shares. The total value of these holdings, in millions, is $485. Among active positions in the latest quarter, 40 holders increased their positions by a total of 2.74 million shares, 24 holders decreased the positions by a total of 1.19 million shares, and 22 holders held their positions. This works out to a net increase in ownership of 1.55 million shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 12 holders initiated new positions by a total of 478503 shares and 7 holders exited their positions by a total of 728158 shares. This nets out to a decrease of 249655 shares and is another bearish sign for COLL.
In the last three months, insiders executed a total of 3 trades. 3 were sells. Insider ownership decreased by a total of 54601 shares, which suggests that COLL’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 13 buys and 10 sells, and ownership increased by a net of 143519 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s short interest is 5.38 million shares, or 28.27% of the float. This represents a decrease of -10% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that COLL is a Strong buy, which implies that COLL is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is undervalued.